News

MPR4d
Twice-Yearly HIV-1 PrEP Yeztugo Gets FDA Approval
Yeztugo (lenacapavir) is an HIV-1 capsid inhibitor that is administered every 6 months after an initial dosing regimen.
The American Journal of Managed Care4d
Understanding How Complement C5 Inhibitors Work in MG: Miriam Freimer, MD
In myasthenia gravis, complement plays a big role in what happens to the muscle end of the neuromuscular junction, explains ...
The American Journal of Managed Care1d
A Closer Look at Nipocalimab’s Impact on Myasthenia Gravis Care: Constantine Farmakidis, MD
Nipocalimab's FDA approval revolutionizes generalized myasthenia gravis treatment, offering rapid symptom relief and improved ...
Medscape5d
Etravirine: A Novel Nonnucleoside Reverse Transcriptase Inhibitor - Medscape
American Journal of Health-System Pharmacy Etravirine: A Novel Nonnucleoside Reverse Transcriptase Inhibitor for Managing Human Immunodeficiency Virus Infection ...
pharmaphorum1d
BMS gets FDA OK for first LAG-3 checkpoint inhibitor
Bristol-Myers Squibb has won FDA approval for the first LAG-3 inhibitor drug ahead of its rivals in cancer immunotherapy, including Merck & Co. The US regulator cleared BMS' LAG-3 drug relatlimab ...
Business Insider2d
YourPath Passive 2045 Moderate CL 1 - Markets Insider
YourPath Passive 2045 Moderate CL 1 Fund 17.51 0.08 0.43% 07/02/2025 12:00 AM NAV Add to watchlist ...
Business Insider2d
IndexSelect Moderate Retire Fund CL I - Markets Insider
IndexSelect Moderate Retire Fund CL I Fund 15.16 0.02 0.15% 07/02/2025 12:00 AM NAV Add to watchlist ...